Daniela Petrić

Daniela Petrić

Auto-generated profile, based on publicly available information

Daniela Petrić

Clinic of Psychiatry, University Hospital Clinic Rijeka, Croatia

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Medical Hypotheses
Verified
Journal Article
Closed access
VRValentino Rački
Valentino Rački
DPDaniela Petrić
Daniela Petrić
NKNatalia Kucic
Natalia Kucic
NKNika Gržeta Krpan
Nika Gržeta Krpan
KJKristina Jurdana
Kristina Jurdana
IRIka Rončević-Gržeta
Ika Rončević-Gržeta

3 April 2019 in Journal of Child and Adolescent Psychopharmacology
Verified
Journal Article
Closed access
DPDaniela Petrić
Daniela Petrić
VRValentino Rački
Valentino Rački
NGNadija Gačo
Nadija Gačo
AKAna Kaštelan
Ana Kaštelan
MGMirjana Graovac
Mirjana Graovac
Objective: The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone. Methods: This study is a retrospective, noninterventional study to assess the effectiveness and tolerability of long-acting injectable antipsychotic paliperidone palmitate in first-episode adolescent patients during the first 12 months of treatment compared with the oral antipsychotic risperidone. The data include general sociodemographic characteristics, number of hospitalizations, side effects, and the following clinical scales: Positive and Negative Syndrome Scale (PANSS), Personal and Social Performance Scale (PSP), Clinical Global Impression Improvement and Severity (CGI-I and CGI-S), and Treatment Satisfaction Questionnaire for Medication (TSQM). Results: During the 12-month study period significant improvement was registered in patients receiving both paliperidone palmitate and risperidone in the following scales: PANSS, PSP, CGI-I, and CGI-S. Patients receiving paliperidone palmitate had significantly greater improvement in PANSS, CGI-S, and PSP compared with the risperidone group. Patients receiving risperidone had significantly higher number of hospitalizations than the patients receiving paliperidone palmitate. The TSQM revealed that the patients who were receiving paliperidone palmitate achieved significantly higher scores on the convenience scale, global satisfaction, and on the overall result, whereas no difference was observed on the effectiveness scale. There were several side effects reported for paliperidone (5.5% hyperprolactinemia, 5.5% weight gain) and risperidone (5.5% hyperprolactinemia, 16.7% weight gain). Conclusions: In conclusion, paliperidone palmitate seems to be safe and effective in adolescent patients. Furthermore, it compared favorably with risperidone in the clinical response, side effects, and hospitalizations.

1 February 2018 in Schizophrenia Research
Verified
Journal Article
Closed access
MKMartina Rojnic Kuzman
Martina Rojnic Kuzman
OAOlivier Andlauer
Olivier Andlauer
KBKai Burmeister
Kai Burmeister
BDBoris Dvoracek
Boris Dvoracek
RLRebekka Lencer
Rebekka Lencer
ASAleksandar Savic
Aleksandar Savic

1 September 2012
Verified
Journal Article
Closed access
MKMiro Klarić
Miro Klarić
TFTanja Frančišković
Tanja Frančišković
EOEdita Cerni Obrdalj
Edita Cerni Obrdalj
DPDaniela Petrić
Daniela Petrić
DBDolores Britvić
Dolores Britvić
NZNikolina Zovko
Nikolina Zovko

1 March 2010
Verified
Journal Article
Closed access
MPMarija Vucić Peitl
Marija Vucić Peitl
DPDaniela Petrić
Daniela Petrić
VPVjekoslav Peitl
Vjekoslav Peitl

15 June 2019 in Archives of Psychiatry Research
Verified
Journal Article
Open access
DPDaniela Petrić
Daniela Petrić
MPMarija Vučić Peitl
Marija Vučić Peitl
JPJoško Prološčić
Joško Prološčić
VPVjekoslav Peitl
Vjekoslav Peitl